PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Richard Kay joined us to present on assessing evaluation time bias, and Gui-shuang Ying presented on prediction of event times via the Weibull distribution.
Chair: Katherine Hutchinson: PSI Vice-Chair & Membership Secretary, Quanticate
Speaker: Richard Kay: RK Statistics Ltd, Great Longstone, UK
On assessing the presence of evaluation-time bias in progression-free survival in randomized trials
Co-authors: Jane Wu, Janet Wittes
Published Online: Jun 21 2010
(Subsequently published in: Pharmaceutical Statistics, Volume 10, Issue 3, pages 213–217, May/June 2011)
Abstract | Paper+ | Slides
Speaker: Gui-shuang Ying: Department of Ophthalmology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Weibull prediction of event times in clinical trials
Co-author: Daniel F. Heitjan
Pharmaceutical Statistics, Volume 7, Issue 2, pages 107-120, April/June 2008
Abstract | Paper+ | Slides
+ Papers available to view from 20th October 2010 to 17th November 2010.
For a flier advertising the event, please click here.
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.